EP2170313A2 - Wässrige formulierungen aus acetaminophen zur injektion - Google Patents
Wässrige formulierungen aus acetaminophen zur injektionInfo
- Publication number
- EP2170313A2 EP2170313A2 EP08837144A EP08837144A EP2170313A2 EP 2170313 A2 EP2170313 A2 EP 2170313A2 EP 08837144 A EP08837144 A EP 08837144A EP 08837144 A EP08837144 A EP 08837144A EP 2170313 A2 EP2170313 A2 EP 2170313A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- approximately
- acetaminophen
- injection
- aqueous formulation
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the invention relates to novel stable aqueous formulations of acetaminophen for injection as well as processes for preparing and using the same.
- Acetaminophen also known as paracetamol, is a common analgesic and antipyretic drug that is used for the relief of fever, headaches, and other minor aches and pains. It is a major ingredient in numerous cold and flu medications and many prescription analgesics.
- U.S. Pat. No. 6,028,222 describes aqueous formulations of acetaminophen containing a buffering agent and a free radical antagonist and/or a free radical scavenger which need to be bubbled with an inert gas through the aqueous solvent in order to remove oxygen from the medium and maintain the stability of acetaminophen.
- U.S. Pat. No. 6,992,218 B2 relates to aqueous formulations with an active principle susceptible to oxidation, for example acetaminophen, wherein the essential means for stabilizing them is deoxygenating by bubbling with an inert gas and/or placing under vacuum until the oxygen content is below 2 ppm.
- the invention relates to novel stable aqueous formulations of acetaminophen for injection as well as processes for preparing and using the same.
- the invention provides new, stable, aqueous acetaminophen formulations.
- the invention relates to a new stable, aqueous acetaminophen formulation that includes: a. approximately 200.0 mg to approximately 1,400.0 mg of acetaminophen; b. approximately 200.0 mg to approximately 10,000.0 mg of mannitol for injection; c. approximately 0.0 mg to approximately 30.0 mg of monobasic sodium phosphate; d. approximately 0.0 mg to approximately 300.0 mg of povidone; e. a sufficient amount of sodium hydroxide (as needed) is added to adjust the pH between approximately 4.0 and approximately 8.0; f. a sufficient amount of hydrochloric acid (as needed) is added to adjust the pH between approximately 4.0 and approximately 8.0; and g. an injection volume of water for injection up to a volume of approximately 100 mL.
- the invention includes a new stable, aqueous composition that includes acetaminophen having the following composition: a. approximately 1,000.0 mg of acetaminophen; b. approximately 3,750.0 mg of mannitol for injection; c. approximately 13.0 mg of monobasic sodium phosphate; d. approximately 100.0 mg of povidone; e. a sufficient amount of sodium hydroxide is added to adjust the pH until approximately 5.5; f. a sufficient amount of hydrochloric acid is added to adjust the pH until approximately 5.5; and g. an injection volume of water for injection up to a volume of approximately 10O mL.
- acetaminophen having the following composition: a. approximately 1,000.0 mg of acetaminophen; b. approximately 3,750.0 mg of mannitol for injection; c. approximately 13.0 mg of monobasic sodium phosphate; d. approximately 100.0 mg of povidone; e. a sufficient amount of sodium hydroxide is added to adjust the pH
- Another embodiment of the invention provides a process for preparing the above- described aqueous composition that includes the following steps: a. adding monobasic sodium phosphate, povidone, mannitol for injection and acetaminophen in a volume of water for injection to form the aqueous formulation; b. if necessary, adding sodium hydroxide or hydrochloric acid to adjust the pH of the aqueous formulation between approximately 4.0 and approximately
- bottles is meant to convey glass or plastic containers or any other materials suitable for containing the aqueous formulations of acetaminophen described herein.
- the invention further includes the use of the aqueous pharmaceutical formulations of acetaminophen according to the invention for the treatment of pain.
- the invention further includes the use of the aqueous pharmaceutical formulations of acetaminophen for the treatment of pain after surgery and treatment of short period of fever when intravenous administration is justified or when others routes of administration are not possible.
- EXAMPLE 1 Aqueous solution of acetaminophen
- Table 1 illustrates a formulation of an aqueous acetaminophen solution with the following constituents:
- the aqueous acetaminophen formulation of Table 1 was prepared by dissolving 13.0 mg of monobasic sodium phosphate, 100.0 mg of povidone, 3,750.0 mg of mannitol for injection and 1,000.0 mg of acetaminophen in 80 mL of water for injection. Then, the pH is checked, and if necessary was adjusted until 5.5 by adding sodium hydroxide or hydrochloric acid. The solution was adjusted to 100 mL by the addition of water for injection. Next, he solution was filtered and filled into a 100 mL bottle. The bottle was then closed under a nitrogen atmosphere and sterilized.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92919207P | 2007-06-18 | 2007-06-18 | |
PCT/IB2008/003217 WO2009047634A2 (en) | 2007-06-18 | 2008-06-18 | Aqueous formulations of acetaminophen for injection |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2170313A2 true EP2170313A2 (de) | 2010-04-07 |
Family
ID=40429866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08837144A Withdrawn EP2170313A2 (de) | 2007-06-18 | 2008-06-18 | Wässrige formulierungen aus acetaminophen zur injektion |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2170313A2 (de) |
AR (1) | AR067048A1 (de) |
WO (1) | WO2009047634A2 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2243477A1 (de) * | 2009-04-22 | 2010-10-27 | Fresenius Kabi Deutschland GmbH | Paracetamol zur parenteralen Verabreichung |
US20120245230A1 (en) * | 2009-12-10 | 2012-09-27 | Tecnimede-Sociedade Tecnico- Medicinal, S.A. | Method and composition for preparing stable liquid formulations of paracetamol |
PT2377516E (pt) | 2010-04-14 | 2012-07-02 | Braun Melsungen Ag | Composição acetaminofeno |
WO2012001494A2 (en) * | 2010-06-30 | 2012-01-05 | Troikaa Pharmaceuticals Limited | Pharmaceutical compositions comprising paracetamol and process for preparing the same |
ZA201300398B (en) * | 2012-11-27 | 2013-09-25 | Genfarma Laboratories S L | Injectable liquid formulation of the combination of tramadol and paracetamol |
CA2969303A1 (en) | 2014-12-20 | 2016-06-23 | Troikaa Pharmaceuticals Limited | Injectable formulations of paracetamol |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2751875B1 (fr) * | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
FR2809619B1 (fr) * | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
FR2851164B1 (fr) * | 2003-02-14 | 2005-04-22 | Xuan Tho Nguyen | Formulation liquide injectable de paracetamol |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
EP1992334A1 (de) * | 2007-05-08 | 2008-11-19 | Docpharma NV/SA | Lagerfähige Formulierung eines oxidationsempfindlichen phenolhaltigen Arzneimittels, insbesondere Paracetamol, mit einer wässrigen, durch ein temperaturgeregeltes Herstellungsverfahren desoxidierten Arzneimittellösung |
-
2008
- 2008-06-18 EP EP08837144A patent/EP2170313A2/de not_active Withdrawn
- 2008-06-18 WO PCT/IB2008/003217 patent/WO2009047634A2/en active Application Filing
- 2008-06-18 AR ARP080102597A patent/AR067048A1/es unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2009047634A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009047634A3 (en) | 2009-06-04 |
WO2009047634A2 (en) | 2009-04-16 |
AR067048A1 (es) | 2009-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6635927B2 (ja) | ノルアドレナリンの安定な低濃度の注射用溶液を生成するための方法 | |
EP1948133B1 (de) | Argatrobanformulierung mit einer säure als lösungsvermittler | |
JP5710462B2 (ja) | 非経口投与を目的とするビンフルニンの医薬組成物、その調製方法およびその使用 | |
JP6892494B2 (ja) | パラセタモール及びイブプロフェンを含む水性配合物 | |
EP2170313A2 (de) | Wässrige formulierungen aus acetaminophen zur injektion | |
WO2009081283A2 (en) | Aqueous formulations of acetaminophen for injection | |
JP2008525136A (ja) | オキサリプラチン用プラスチック瓶 | |
JP4959335B2 (ja) | メチルフェニデート溶液および関連する投与および製造方法 | |
US20030181527A1 (en) | Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone | |
AU2001260935A1 (en) | Novel formulations of alpha-2,4-disulfophenyl-N-tert-butylnitrone | |
RU2242231C2 (ru) | Парентеральная композиция для лечения эпилепсии | |
KR102246136B1 (ko) | 산화-민감성 제형을 위한 안정한 즉석 사용식 주입 백을 제조하는 방법 | |
WO2019150381A1 (en) | A stable pharmaceutical composition and process for production of isoproterenol hydrochloride injection | |
WO2014083071A1 (en) | Injectable liquid formulation of the combination of tramadol and paracetamol | |
CN114286669A (zh) | 去甲肾上腺素的输注剂型 | |
WO2007069070A2 (en) | Aseptically filled multidose injectable dosage forms of granisetron | |
US20160144033A1 (en) | Concentrated acetaminophen solution | |
EP3222271A1 (de) | Stabile pharmazeutische zusammensetzung mit pemetrexed oder einem pharmazeutisch akzeptablen salz davon | |
WO2010045682A1 (en) | Storage stable compositions and methods for preparing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100118 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17Q | First examination report despatched |
Effective date: 20100413 |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MEDICHEM, S.A. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20161125 |